Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > That top 10 pharma?
View:
Post by Alex1726 on Dec 11, 2020 8:53pm

That top 10 pharma?

Could it be J&J?
Comment by Alex1726 on Dec 11, 2020 9:03pm
Could SBM be a good target for J&J ? J&J has hands in this two words, cosmetics and pharma , don't they own a SGLT 2  DIABETIC DRUG? Yes i think so.
Comment by MirrorWorldMan on Dec 12, 2020 4:12pm
J & J is not interested in another meetoo SGLT2, they have Canagliflozin, first to market but second in market share behind Empagliflozin, then Dapaglifozin is a far distant 3rd.  Cana dropped to second because of less efficacious endpoint data on Renal and CV outcomes in their trials.  But patterns of practice are changing and now their is prophylaxis use with this class.  But ...more  
Comment by JohnFriesen on Dec 12, 2020 6:18pm
This post has been removed in accordance with Community Policy
Sirona Biochem Corp
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities